All articles by Vidya Sagar Maddela
Vidya Sagar Maddela
Roche signs agreement to acquire 89bio in $2.4bn deal
The deal is anticipated to close in Q4 2025, subject to customary closing conditions.
GSK plans $30bn investment for R&D in US
The investment includes a $1.2bn package for advanced manufacturing, AI and digital technologies.
Cadrenal Therapeutics acquires eXIthera’s Factor XIa inhibitors
Cadrenal will acquire eXIthera’s intravenous Factor XIa inhibitor frunexian, oral inhibitor EP-7327, and additional novel FXIa small molecules.
Novo Nordisk secures EMA approval for Rybelsus label update
Rybelsus becomes the first oral glucagon-like peptide-1 receptor agonist in the EU with proven cardiovascular benefits.
AstraZeneca halts £200m research investment in Cambridge
The British drugmaker shelved a separate £450m ($612m) investment in a vaccine manufacturing plant in northern England, earlier this year.
Amneal secures FDA approval for sodium oxybate solution
The sodium oxybate oral solution is prescribed for managing cataplexy and excessive daytime sleepiness (EDS) in individuals with narcolepsy.
Lilly launches TuneLab platform to enhance drug discovery
The launch of TuneLab represents an expansion of Lilly’s Catalyze360 programme, which supports early-stage drug development.
Novartis to acquire US drugmaker Tourmaline Bio for $1.4bn
Tourmaline Bio is developing pacibekitug, an anti-IL-6 monoclonal antibody, for the treatment of atherosclerotic cardiovascular disease.
Servier acquires Kaerus’ Fragile X syndrome candidate for up to $450m
KER-0193 targets BK channel dysfunction and has shown promise in improving symptoms related to Fragile X syndrome in preclinical studies.
Epigenic secures $60m financing to advance preclinical assets
The company will use the funds to advance the clinical development of EPI-003 for chronic hepatitis B and EPI-001 for hypercholesterolemia.